Vagus Nerve Stimulation Market Report 2025

This vagus nerve stimulation market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The vagus nerve stimulation market size has grown rapidly in recent years. It will grow from $0.89 billion in 2024 to $1.02 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to rising geriatric population, prevalence of depression, increasing awareness and acceptance of alternative therapies, growing prevalence of epilepsy, and increasing incidence of chronic diseases.

The vagus nerve stimulation market size is expected to see rapid growth in the next few years. It will grow to $1.76 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to the growing prevalence of treatment-resistant depression, rising adoption of minimally invasive neurosurgical procedures, rising research and development (R&D) initiatives, improving healthcare infrastructure, and increasing prevalence and incidence of neurological disorders. Major trends in the forecast period include technological advancements, innovations in product design, robot-assisted implantation, electrical stimulation devices, and innovating stimulation techniques.

The rising prevalence of neurological disorders is expected to drive the growth of the vagus nerve stimulation market in the coming years. Neurological disorders are conditions that impact the brain, spinal cord, or nerves, resulting in issues with movement, sensation, cognition, or overall functionality. The causes of these disorders are varied, often involving a combination of genetic, environmental, and lifestyle factors. Moreover, physical injuries, such as head trauma and spinal cord injuries, can also lead to neurological issues. Vagus nerve stimulation is utilized to manage these disorders by modulating brain activity and neurotransmitter levels, which helps alleviate symptoms associated with conditions such as epilepsy, depression, and specific types of migraines. For instance, in September 2024, the Australian Institute of Health and Welfare, a government agency in Australia, estimated that approximately 411,100 Australians were living with dementia in 2023, with projections indicating that this number will more than double by 2058. Thus, the increasing prevalence of neurological disorders is fueling the growth of the vagus nerve stimulation market.

Key players in the vagus nerve stimulation market are developing advanced products such as implantable pulse generators (IPGs) to provide long-term, adjustable, and targeted therapy for chronic conditions. An implantable pulse generator (IPG) is a device implanted under the skin that delivers electrical pulses to treat conditions such as chronic pain or neurological disorders. For example, in February 2023, LivaNova Plc, a UK-based medical device company, introduced the SenTiva DUO, a specialized IPG for vagus nerve stimulation (VNS) therapy aimed at drug-resistant epilepsy. This device allows patients with older dual-pin systems to upgrade without lead revisions, offering advanced VNS therapy with customizable and automatic delivery. The SenTiva DUO enhances seizure control and supports better treatment adherence, marking a significant advancement in managing these conditions.

In June 2023, SCREEN Holdings Co. Ltd., a semiconductor company based in Japan, acquired shares in Adriakaim Inc. for an undisclosed amount. Following this acquisition, SCREEN plans to work with Adriakaim to accelerate the commercialization of its vagus nerve stimulation devices. SCREEN will also continue to address various needs within the medical field, contributing to solutions for societal issues. Adriakaim Inc. is a Japanese manufacturer specializing in vagus nerve stimulation devices.

Major companies operating in the vagus nerve stimulation market are Medtronic PLC, Stryker Corporation, Boston Scientific Corporation, Dignity Health, LivaNova LLC, NeuroTek Inc., Neurospace Inc., ReShape Lifesciences Inc., electroCore Inc., Adriakaim Inc., Soterix Medical Inc., Nexstim PLC, Cleveland Medical Devices Inc., MicroTransponder Inc., Parasym Ltd., Neuvana LLC, NeuroSigma Inc., Evren Technologies Inc., Integrative Health Technologies Inc., Aucta Technologies Inc.

North America was the largest region in the vagus nerve stimulation market in 2023. The regions covered in the vagus nerve stimulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vagus nerve stimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Vagus nerve stimulation (VNS) is a medical treatment that involves delivering electrical impulses to the vagus nerve, a major nerve extending from the brainstem to the abdomen. This treatment affects various bodily functions, including heart rate, digestion, and mood regulation. It is primarily used to manage conditions such as epilepsy, treatment-resistant depression, and other neurological disorders.

The main products for vagus nerve stimulation include implantable VNS devices and external VNS devices. An implantable VNS device is surgically placed in the body, typically in the neck, to deliver electrical impulses to the vagus nerve. It is designed using various biomaterials, such as metals, ceramics, and polymers, and is used for treating epilepsy, depression, and migraines. These devices are utilized in several settings, including hospitals, neurology clinics, ambulatory surgical centers, and research institutions.

The vagus nerve stimulation market research report is one of a series of new reports that provides vagus nerve stimulation market statistics, including vagus nerve stimulation industry global market size, regional shares, competitors with a vagus nerve stimulation market share, detailed vagus nerve stimulation market segments, market trends and opportunities, and any further data you may need to thrive in the vagus nerve stimulation industry. This vagus nerve stimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vagus nerve stimulation market consists of sales of non-invasive VNS devices, stimulation generators, lead wires and electrodes, rechargeable VNS devices and wearable VNS patches. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.